What Cafergot Treats: Main Uses and Benefits

The medication is commonly used across conditions presenting with acute episodes of severe head pain, supporting patients experiencing the distressing manifestations of vascular-related headaches. This combination product is used for the acute management of vascular headaches, including specific conditions such as established migraine attacks and certain forms of cluster headaches.

---

Acute Abortive Treatment for Severe Vascular Headaches

This therapeutic domain is relevant for easing symptoms that become more disruptive during flare-ups of conditions characterized by heightened physiological activity. It is applied across domains where additional symptomatic support is needed to address the intense, pulsating pain and other severe symptoms that accompany these episodes. This approach may assist with managing the symptom escalation during acute episodes, providing supportive relief when symptoms interfere with routine activities.

“This medication is commonly used to help patients cope more steadily with the difficult, acute phase of a headache that is disruptive to daily life.”

---

Intervention for Symptom Patterns Unresponsive to Standard Support

Cafergot is generally used in situations involving certain distressing symptoms when general symptomatic support is not providing adequate assistance. It supports patients during difficult episodes by easing the symptom load in cases of recurrent, severe headache episodes when symptoms are difficult to tolerate and standard symptomatic assistance is not sufficient. This contributes to easing the overall symptom burden, helping improve day-to-day comfort during symptomatic periods.

---

Quick Fact: Relief for Intense Vascular Pain The medicine is used for the short-term, acute management of severe, episodic head pain in patients where additional management of discomfort is required.

Regulatory References

1. NIH's NCBI database on Ergotamine/Caffeine

Eligibility Map: Who Can and Cannot Use Cafergot — Official Regulatory Information

Populations for whom use is allowed (as stated in label):

• Adults without underlying contraindications.

---

Populations for whom use is contraindicated:	Category	Contraindication
Cardiovascular/Vascular	Ischemic Heart Disease (including angina or MI), Peripheral Vascular Disease, Severe Hypertension.
Organ Function	Severe Hepatic Impairment (severe liver disease), Severe Renal Impairment (severe kidney disease).
Physiological Status	Pregnancy (Category X) and Nursing Mothers (breastfeeding).
Systemic Health	Severe Infection or Sepsis.

---

Age-related eligibility rules:	Age Group	Eligibility Status
Children under 12	Use is not recommended; safety and efficacy are not established.
Older adults (over 65)	Use is not recommended due to limited experience and cardiovascular risk.

---

Eligibility-related restrictions:

• Prohibited Co-administration: Use is strictly contraindicated with potent CYP3A4 Inhibitors (e.g., Macrolide antibiotics) or another 5-HT1 agonist (Triptan) within 24 hours.
• Clinical History: Use is restricted in patients with a history of developing Fibrotic Complications related to prior ergot derivative use.

Connection to the overall eligibility profile

The official regulatory label defines the eligible population as adults who do not have pre-existing vascular disease or severe organ dysfunction. The extensive list of absolute contraindications rigorously excludes patients in specific physiological states (pregnancy, lactation) and those with underlying conditions where the drug's vasoconstrictive effects pose significant risks. Use is not recommended for pediatric or geriatric populations due to insufficient safety data.

️ Interactions with other medicines and products

Category	Official Regulatory Statement
Contraindicated Combinations	The co-administration of Potent CYP 3A4 Inhibitors (including certain macrolide antibiotics, HIV protease inhibitors, and azole antifungals) is strictly prohibited. This restriction is due to the potential for a significant increase in Ergotamine serum levels, which raises the risk of life-threatening peripheral ischemia (ergotism).
	5-HT1 Receptor Agonists (Triptans) and other vasoconstrictors are also contraindicated due to the risk of severe, additive vasoconstrictive effects.
Exposure-Modifying Interactions	Ergotamine is primarily cleared via the CYP 3A4 enzyme. Any medicinal products that inhibit this enzyme, such as Grapefruit Juice, may increase the body’s exposure to Ergotamine. Conversely, medications that induce CYP 3A4 may reduce Ergotamine's expected activity.
Timing Rules and Restrictions	A mandatory 24-hour separation is required between the administration of Cafergot and any 5-HT1 Receptor Agonist (Triptan) to mitigate additive vascular risk. Nicotine from tobacco products and certain Beta-blockers (e.g., Propranolol) are documented to potentiate the drug’s vasoconstrictive action, requiring caution.
Population-Specific Risk	The medication is formally contraindicated in patients with impaired hepatic or renal function. This restriction is based on the inability to adequately clear Ergotamine, which significantly heightens the interaction-related risk of toxicity.

Connection to the Overall Interaction Profile

Regulatory documents establish that the official interaction profile is defined by the drug’s metabolic reliance on the CYP 3A4 enzyme and its intrinsic vasoconstrictive pharmacodynamic activity. These factors mandate the prohibition of combining Cafergot with substances that block its clearance or intensify its vascular effects.

Cafergot is a fixed-dose combination drug that modulates vascular and neurochemical signaling through two distinct mechanistic domains. The action is primarily driven by ergotamine, with caffeine functioning as an auxiliary agent.

Modulation of Vasoactive Receptors

Ergotamine functions as a partial agonist at multiple neurotransmitter receptors, specifically the 5-HT1B and 5-HT1D serotonin receptor subtypes and alpha-adrenergic receptors. Engagement with these receptors, primarily on the smooth muscle of cranial blood vessels, particularly extracranial arteries, initiates a vasoconstrictive effect. This mechanism alters the hyperresponsive state within the cranial circulation.

Augmentation of Ergotamine Activity

Caffeine, the secondary component, functions as an antagonist at adenosine receptors, contributing independent vasoconstrictive properties that modulate the overall state of vasodilation. Additionally, caffeine modifies the pharmacokinetics of ergotamine by facilitating its absorption in the gastrointestinal tract, which affects the temporal profile of target engagement.

Official Administration Routes and Dosing

Cafergot (ergotamine and caffeine) is officially approved for use in two distinct forms and routes of administration: as an oral tablet and as a rectal suppository.

---

Dosing Schedule for Acute Use

Administration of this medicine is structured for intermittent, acute use and should begin at the first sign of a vascular headache for maximum effectiveness. It is not intended for chronic daily administration.

Administration Route	Initial Dose	Supplemental Doses (If Needed)	Maximum Dose per Attack	Maximum Dose per Week
Oral Tablet (1 mg Ergotamine)	2 tablets	1 tablet every 30 minutes	6 tablets	10 tablets
Rectal Suppository (2 mg Ergotamine)	1 suppository	1 suppository after 1 hour	2 suppositories	5 suppositories

Procedural and Population Constraints

Official labeling specifies critical usage limits and conditions. The total amount of medicine taken must not exceed the defined maximums for a single headache or over a seven-day period. The oral tablet may be taken with or without food. However, patients are instructed to avoid consumption of grapefruit and grapefruit juice while using this medication. Safety and efficacy have not been established for use in the pediatric population, and there is generally no information available regarding its use in geriatric patients. The rectal route is typically employed when excessive nausea or vomiting prevents oral retention.

Research Evidence / Overview of Studies for Cafergot

Research Evidence for Acute Vascular Headaches

Studies utilized short-term randomized controlled trials (RCTs) to examine the ergotamine/caffeine combination for immediate symptoms of vascular headaches, particularly migraine attacks, in adult patients. Research examined outcomes related to both measures related to changes in pain (headache response) and pain-free status in the hours following administration. Findings were mixed across different studies concerning the long-term patterns of relief and recurrence rates.

Comparative Research Landscape

Research has explored the combination's performance by comparing it directly to newer drug classes, such as triptans. These comparative trials assess patient-reported experiences regarding the speed and completeness of symptom relief. The evidence level is generally described as moderate; the overall assessment suggests that evidence quality varies across studies.

Evidence in Specific Populations

Research describes that the original clinical trials primarily focused on adult patients. For age groups where data is often limited, such as children and adolescents (under 18) and older adults (over 65), data are still emerging or evidence is limited. Subgroup findings are uncertain for these categories, meaning results apply only to the populations studied in the core clinical program.

Long-Term Evidence and Chronic Use Patterns

Long-term effects are not fully established by prospective, long-duration trials. Research exploring long-term use is largely conducted in observational settings, tracking health status in patients who use the medicine in patterns beyond acute, short-term use. The follow-up durations were limited in efficacy trials, meaning there is limited information for long-term outcomes.

Summary of Evidence Gaps and Quality Assessment

The research base for Cafergot was studied for its intended use but presents certain limitations acknowledged in scientific reviews. Evidence quality varies, and certainty remains low in some areas. The main limitations include modest sample sizes in older studies and a lack of comparative evidence for some current therapeutic options. The research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Key Studies & References

1. Ergotamine/Caffeine - StatPearls - NCBI Bookshelf - NIH (Indications and Study Scope)
2. Treatment of migraine attacks and preventive treatment of migraine - International Headache Society (Clinical Guidelines & Comparative Research)

Common questions about Cafergot (FAQ)

---

Q: Can taking Cafergot cause problems with blood circulation?

Official documentation states that because the medication has vasoconstrictive properties (meaning it causes blood vessels to narrow), neurological effects such as paresthesias are listed as potential adverse effects. Paresthesias are described as tingling, numbness, or a 'pins and needles' feeling, often in the fingers or toes. These sensations are also listed among the symptoms related to potential overexposure or overdose.

---

Q: What is meant by the term 'ergotism' in relation to Cafergot?

Ergotism is documented as a serious adverse reaction linked to the drug's properties. It is officially described as a syndrome involving the intense constriction of peripheral blood vessels, which can lead to a condition called ischemia (lack of adequate blood flow) in the extremities. This condition is documented as an acute drug toxicity syndrome resulting from the compound's vascular effects.

---

Q: Does the efficacy of Cafergot change over time with continued use?

Continuous daily administration is officially contraindicated (not recommended) due to the risk of serious complications, including the potential for headache patterns to develop into Medicine Overuse Headache (MOH). MOH is associated with use exceeding recommended limits and is characterized by an increase in headache frequency or severity.

---

Q: Are there documented interaction risks with common supplements, such as St. John's Wort?

Regulatory information notes that the drug is processed by the CYP 3A4 enzyme in the body. Any substance that affects this enzyme, whether a medicine or an herbal supplement like St. John's Wort, has the potential to alter the body’s exposure to the drug or change its expected activity.

---

Q: Is a doctor's prescription always required to get Cafergot?

Yes. The official labeling for this medication designates it as 'Rx only' (Prescription only) in the United States and other regions where it is available. The drug is available only through a prescription because of its specific classification and established risk profile.

---

Q: Is it true that Cafergot has been around for a long time?

Regulatory and historical documentation indicates that the medication, or similar formulations, has been in use for several decades. For example, records show its initial approval in some countries dating back to the late 1960s.

---

Q: Do I need to avoid any specific foods or drinks while taking Cafergot?

Official prescribing information specifically instructs patients to avoid the consumption of grapefruit and grapefruit juice while using the medication. This restriction is based on the potential for grapefruit to increase the body's exposure to the drug's active components.

---

Q: Can Cafergot be taken at the same time as cold or flu medicines?

Official warnings prohibit combining this medication with other vasoconstrictors or potent CYP 3A4 inhibitors. Since some cold and flu preparations contain components from these categories, there is a documented potential for additive vasoconstrictive or exposure-modifying interactions described in the regulatory label.

---

Q: What are the risks if I accidentally take more Cafergot than is generally described?

Exceeding the maximum defined doses significantly increases the risk of serious adverse symptoms. The key serious risk associated with overexposure is ergotism, a syndrome of intense blood vessel constriction that can lead to potential ischemia (reduced blood flow) in the extremities.

---

Q: Are there specific symptoms that require immediate medical attention after taking Cafergot?

Official documents list symptoms that should prompt immediate medical evaluation. These include signs of peripheral ischemia (e.g., numbness, tingling, pain, or coldness in the fingers or toes), chest pain, or confusion, which are related to serious adverse reactions.

---

Q: What should be done if Cafergot doesn't seem to be working?

Official patient information often indicates that if headache relief is not achieved after using the medication, it may signal the need for a change in treatment strategy. In such cases, continued lack of relief may signal the need to evaluate alternative acute migraine management options with a healthcare provider.

---

Q: Does Cafergot interact with alcohol consumption?

While regulatory labels do not list alcohol as a major drug-to-drug interaction, patient guidance published by official sources may advise caution with alcoholic beverages.

---

Q: Are there any warnings about operating machinery while using Cafergot?

Due to potential adverse effects such as dizziness and vertigo (a sensation of spinning) listed in official documents, caution is advised regarding activities requiring high levels of focus, such as driving or operating machinery.

---

Q: Is Cafergot approved for use in all countries worldwide?

Official records show that its availability and regulatory status vary globally. For example, regulatory action in some countries has led to the discontinuation of distribution following updated risk-benefit assessments for the combination drug.

---

Q: What is the full list of inactive ingredients in Cafergot according to official labels?

Official drug labels are required to list all inactive ingredients, in addition to the active components (ergotamine and caffeine). This comprehensive list, which varies by specific product and form, can be found in the product’s official regulatory document.

The storage and disposal of Cafergot (Ergotamine Tartrate and Caffeine) are strictly regulated by the official instructions provided for its two forms.

Official Storage Requirements

Form	Temperature Requirement	Container/Protection Rule
Tablets	Controlled Room Temperature (20 C to 25 C)	Store in a tight, light-resistant container.
Suppositories	Store below 25 C (77 F)	Store in a tight container and protect from moisture.

All forms of the medicine must be kept out of the reach of children to prevent accidental exposure.

Disposal Requirements

Expired or unused Cafergot must not be disposed of in the household trash or flushed down the toilet. Official regulatory guidance requires asking a pharmacist or other healthcare professional for instruction on proper disposal, which typically involves community drug take-back programs.